Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Neoplasms 1Liver Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

Bevacizumab 35durvalumab 23atezolizumab 22Nivolumab 20lenvatinib 19tremelimumab 16Specimen Handling 14Magnetic Resonance Spectroscopy 12sintilimab 11pembrolizumab 9Ipilimumab 9tislelizumab 7Sorafenib 7cabozantinib 5X-Rays 5Immunoglobulin G 5Disulfides 5Cyclophosphamide 5regorafenib 4Radiotherapy 4Radiosurgery 4Radiation 4Oxaliplatin 4Immunotherapy 4Ethiodized Oil 4fludarabine 3donafenib 3Surgical Procedures, Operative 3Folfox protocol 3Fluorouracil 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × E-7386 × 90 days × Clear all
NCT04008797 2026-03-24

A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

Eisai Inc.

Phase 1/2 Active not recruiting
301 enrolled
GastrointestinalGynecologic

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡